This equates to a 10% increase in vision, this is highly...

This equates to a 10% increase in vision, this is highly important and I don't know a person on earth who wouldn't give anything to increase their poor vision by another entire line on the sight chart.

OPT have a product that will be incorporated in every medicine treating this condition in the world as a standard of care.

This is only 15 months away, but im excited by the second 900 person Phase 3 trial being filled next month, then mid trial readouts for both Phase 3 trials come November.

2 years from now I am expecting this to plato at $4B market cap and then increase with earnings to 8x turnover which I know is modest as it can be 20x in this market. And OPT will be turning over a minimum of $2B per annum. The maths on OPT are astounding, and will soon be mainstream, the importance of a huuge 900 person Phase 3 trial will sink in when the results replicate the other huge Phase 2b trial in 300 people.

In the ASX the rewards of being in this company at this point in time is unbeatable, what is 2 years making pips when holding OPT will bring in rewards unlike anything available in this price range at this point in Phase 3 trials. This has the makings of a $10b company. Patience all, OPT are closer than the market understands